Most Recent Articles by Lauren Grygotis, Editor
The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of osteoarthritis.
Health and social service utilization decreased in immigrant communities after the 2016 presidential election.
The ACR and EULAR have developed draft classification criteria for giant cell arteritis and Takayasu arteritis.
Treatment with filgotinib over 24 weeks resulted in significant improvements in the signs and symptoms of RA among patients with inadequate response or intolerance to biologic DMARDs.
Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.
More Articles by Lauren Grygotis, Editor
Rheumatology Advisor Articles
- Ultrasonography in Gout: Potential Applications for Diagnosis and Patient Monitoring
- Immunogenicity of Golimumab Validated Using Novel Anti-Drug Antibody Detection Assay
- Similar Long-Term Outcomes in Early- vs Late-Onset Lupus Nephritis
- Radiographic Knee OA Not Correlated With Diabetes, Altered Glucose Metabolism
- Serum sRAGE Correlated With Disease Activity in Rheumatoid Arthritis
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments?
- Examining Insurance Complications in the Shared Decision Making Process for Rheumatoid Arthritis
- Smoking Linked to Cognitive Dysfunction in Fibromyalgia
- Patient Education Can Improve Chronic Disease Management
- Health-Enhancing Physical Activity Program Reduces Global Pain in RA
- Chronic Opioid Use Has Doubled Since 2002 Among Patients With RA
- Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
- Flaws, Potential Solutions for Physician Incentive Programs Examined
- Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis
- Gene Polymorphisms Predict Response to Tocilizumab, Rituximab in RA